Join
Live feed
·
INSIDERFilingvia Quantisnow
Prelude Therapeutics Incorporated logo

CLO, Interim CFO, Corp Sec. Lim Bryant David bought $22,638 worth of shares (25,000 units at $0.91), increasing direct ownership by 1,042% to 27,400 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRLD (Prelude Therapeutics Incorporated) and more on Quantisnow.

CLO, Interim CFO, Corp Sec. Lim Bryant David bought $22,638 worth of shares (25,000 units at $0.91), increasing direct ownership by 1,042% to 27,400 units (SEC Form 4) | Quantisnow